Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies
|
|
- Florence French
- 5 years ago
- Views:
Transcription
1 Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies Copyright All Rights Reserved. Property of Theratechnologies Inc.
2 Mechanism of Action of Tesamorelin EGRIFTA (tesamorelin for injection) is a Synthetic Analogue of Human Growth Hormone-Releasing Factor (GRF) EGRIFTA stimulates the pituitary to synthesize and secrete growth hormone In vitro, EGRIFTA binds and stimulates human GRF receptors with similar potency as the natural GRF EGRIFTA EGRIFTA binds to receptor Receptor Growth Hormone Release of growth hormone Copyright All Rights Reserved. Property of Theratechnologies Inc.
3 Growth Hormone (GH) Regulation and Physiology + GHRH - Somatostatin (-) GH Growth Muscle Mass IGF-I Synthesis Lipolysis
4 Rietschel et al. J Clin Endocrinol Metab Growth Hormone Secretion is Reduced in HIV-Related Lipodystrophy
5 Phase 3 Clinical Studies of EGRIFTA TM (tesamorelin for injection) Main Phase (Weeks 0-26) Extension Phase (Weeks 26-52) EGRIFTA TM 2:1 Randomization EGRIFTA TM Randomization (3:1 ratio for Study 1) (1:1 ratio for Study 2) (E-E)* PLACEBO (E-P) Placebo EGRIFTA TM (P-E) *E-E= EGRIFTA (tesamorelin for injection) for weeks 0-26 and EGRIFTA for weeks E-P= EGRIFTA for weeks 0-26 and placebo for weeks P-E= Placebo for weeks 0-26 and EGRIFTA for weeks Copyright All Rights Reserved. Property of Theratechnologies Inc. Falutz et al. J Clin Endocr Metab
6 Inclusion and Exclusion Criteria Main Inclusion Criteria HIV+ male or female patient, years Waist circumference 95 cm (37.4 inches) and a waist-to-hip ratio 0.94 for men and waist circumference 94 cm (37.0 inches) and waist-to-hip ratio 0.88 for women Fasting blood glucose (FBG) <150 mg/dl (<8.33 mmol/l) Stable antiretroviral regimen for 8 weeks prior to randomization For inclusion into the extension phase, patients must have completed the main phase with (FBG) 150 mg/dl Main Exclusion Criteria BMI 20 kg/m 2 Type 1 diabetes, type 2 diabetes if previously treated with insulin or with oral hypoglycemic or insulin sensitizing agents History of malignancy Hypopituitarism. Copyright All Rights Reserved. Property of Theratechnologies Inc. Falutz et al. J Clin Endocr Metab
7 Study Endpoints Primary study endpoint Percentage change from baseline in visceral adipose tissue (VAT) vs placebo at week 26 VAT and changes in VAT were assessed using CT Scans at L4-L5 vertebral level Secondary study endpoints Patient-reported outcomes related to body image Triglycerides Ratio of total cholesterol to HDL cholesterol IGF-1 levels Safety parameters Other Endpoints Waist circumference Abdominal subcutaneous tissue (SAT) Trunk fat Lean body mass Copyright All Rights Reserved. Property of Theratechnologies Inc. Falutz et al. J Clin Endocr Metab
8 Baseline Characteristics (combined studies: 0-26 weeks) Tesamorelin (N=543) Placebo (N=263) P-value Age (y) 48 ± 7 48 ± 8 NS Gender (Male/Female) 465 / / 43 NS Ethnic Origin (W/AA/H) 418 / 71 / / 34 / 25 NS BMI (kg/m 2 ) 29 ± 4 29 ± 4 NS Viral Load, undetectable (%) NS CD4 cell count (cells/mm 3 ) 603 ± ± 281 NS W: White/Caucasian; AA: African American/Black; H: Hispanic. Data are Mean ± SD. NS: Not significant. Falutz et al. J Clin Endocr Metab
9 Baseline Characteristics (combined studies: 0-26 weeks) (Cont d) Tesamorelin (N=543) Placebo (N=263) P-value IGF-1 (ng/ml) 154 ± ± 69 NS Fasting Glucose (mg/dl) 98 ± ± 16 NS TG (mg/dl) 245 ± ± 144 NS WC at Screening (cm) 105 ± ± 9 NS VAT (cm 2 ) 182 ± ± 87 NS SAT (cm 2 ) 231 ± ± 123 NS Limb Fat (kg) (by DEXA) 7.3 ± ± 4.4 NS Data are Mean ± SD. NS: Not significant. Falutz et al. J Clin Endocr Metab
10 Percent Tesamorelin decreases visceral adipose tissue (VAT) and preserves subcutaneous adipose tissue (SAT) Percent Week 26 Week ** VAT SAT -20 VAT SAT Tesamorelin Placebo T-T T-P P-T Data are Mean ± SEM; **P<0.001 vs. Placebo; P<0.001 vs. Baseline and vs. T-P; P<0.001 vs. Baseline. Falutz J. et al. J Clin Endocr Metab. 2010;95:4291.
11 cm cm Tesamorelin significantly reduces waist circumference Week 26 Week ** Waist Circumference -4.0 Waist Circumference Tesamorelin Placebo T-T T-P P-T Data are Mean ± SEM. **P<0.001 vs. Placebo. P<0.001 vs. Baseline and vs. T-P. P<0.001 vs. Baseline. Falutz J. et al. J Clin Endocr Metab. 2010;95:4291.
12 Falutz J. et al. J Clin Endocr Metab. 2010;95:4291. Tesamorelin improves lipid profile (Week 26)
13 Tesamorelin decreases triglycerides in patients with atherogenic dyslipidemia Data are mean ± SEM. **, p=0.01 for tesamorelin ALP(+) vs. tesamorelin ALP(-). An atherogenic was defined as TGs 75 th percentile plus HDL-C 25 th percentile (Wyszynski DF et al. Am J Cardiol. 2005), while an ALP(-) pattern included patients with TGs median plus HDL-C median at baseline Falutz J. et al. CROI 2009.
14 Tesamorelin synergizes with fibrates to decrease triglycerides (% change from baseline) 10.0 Falutz J. et al. CAHR 2016
15 mg/l μg/ml ng/ml ng/ml Tesamorelin Improves inflammatory markers PAI tpa P= P= CRP 1.5 Adiponectin P= P=0.03 Data are Mean ± SEM. Tesamorelin Placebo Stanley T. et al. AIDS 2011;25:1281.
16 Change from baseline Tesamorelin improves belly appearance distress Towards Encouraging or Less Distress P=0.002 ** 10 8 ** Placebo Tesamorelin Data are mean ± SEM. **, P < vs. Baseline for the within group comparison; displayed p-value is for the between group comparisons. A positive change indicates improvement in belly appearance distress. Falutz J. et al. J Clin Endocr Metab. 2010;95:4291.
17 Change in Glucose Parameters at Week 26 (Combined Studies) Baseline Change from Baseline to Week 26 Parameter Tesamorelin (N=543) Placebo (N=263) Tesamorelin (N=543) Placebo (N=263) Mean ± SD Fasting glucose (mmol/l) 5.45 ± ± ± ± hr OGTT glucose (mmol/l) 6.26 ± ± ± ± 2.37 Insulin (pmol/l) ± ± ± ± HOMA-IR 5.5 ± ± ± ± 7.09 HbA 1c (%) 5.3 ± ± ± ± Statistically significantly different between the tesamorelin and placebo groups (p=0.0004). Falutz J. et al. J Clin Endocr Metab. 2010;95:4291.
18 AEs 5% and Occurring More Frequently in Tesamorelin-Treated Patients (Combined Studies) Main Phase (0-26 Weeks) T (N=543) P (N=263) Extension Phase (27-52 Weeks) T-T (N=246) T-P (N=135) Patients with Adverse Events n (%) 425 (78.3) 187 (71.1) 154 (62.6) 81 (60.0) Injection site reactions Injection site erythema 46 (8.5) 7 (2.7) 3 (1.2) 0 Injection site pruritus 41 (7.6) 2 (0.8) 5 (2.0) 0 GH-related events Arthralgia 72 (13.3) 29 (11.0) 14 (5.7) 8 (5.9) Pain in extremity 33 (6.1) 12 (4.6) 8 (3.3) 1 (0.7) Peripheral edema 33 (6.1) 6 (2.3) 5 (2.0) 0 Myalgia 30 (5.5) 5 (1.9) 3 (1.2) 0 Falutz J. et al. J Clin Endocr Metab. 2010;95:4291.
19 Responders Analysis Copyright All Rights Reserved. Property of Theratechnologies Inc.
20 Proportion of Responders and Non Responders at Week 26 Intent-to-treat population, last observation carried forward analysis - Tesamorelin: 57.4% responders* - Placebo: 29.3% responders Per-protocol population, observed case analysis - Tesamorelin: 68.8% responders* - Placebo: 32.6% responders *The proportion of responders and non-responders is statistically different between the tesamorelin and placebo groups in both analyses (p< 0.001)
21 Change in VAT (%) Changes in VAT: Responders vs. Non Responders 15,0 5,0-5,0-15,0-25,0-35,0 VAT Responders VAT VAT Non-Responders No statistical analyses were performed to compare Responders vs Non-Responders Per protocol- Observed Case analysis. Data are Mean ± SEM
22 VAT Profile over 26 Weeks (Responders vs. Non Responders) cm cm 2 (10%) cm cm cm 2 (-27%) 110 Baseline Week 13 Week 26 Responders Non-Responders Per protocol- Observed Case analysis. Data are Mean ± SEM
23 cm Waist Circumference Profile over 26 Weeks (Responders vs. Non Responders) cm cm cm cm 98 Baseline Week 13 Week 26 Responders Non-Responders Per protocol- Observed Case analysis. Data are Mean ± SEM
24 Change (mg/dl) Changes in Lipids Parameters at Week 26 (Responders vs. Non Responders) Total Chol. Non-HDL Chol. Triglycerides P=0.014 P= P=0.005 VAT Responders Per protocol- Observed Case analysis. Data are Mean ± SEM VAT Non-Responders
25 Change from Baseline Towards Encouraging or Less Distress 20 Change in Belly Appearance Distress at Week 26 (Responders vs. Non-Responders) P< VAT Responders VAT Non-Responders Per protocol Observed case analysis; Data are mean ± SEM. Displayed P-values are for the between group comparisons
26 Changes in Glucose Parameters at Week 26 (Responders vs. Non-Responders) Parameter Responders (N= 229) Baseline N-responders (N=98) Mean ± SD Change from Baseline to Week 26 Responders (N= 229) N-responders (N=98) Fasting glucose (mg/dl) 5.4 ± ± ± ± hr OGTT glucose (mmol/l) 6.3 ± ± ± ± 2.4 Insulin (pmol/l) ± ± ± ± 93.8 HOMA-IR 5.38 ± ± ± ± 4.26 HbA 1c (%) 5.26 ± ± ± ± p< 0.05 Responders vs N-responders per protocol Observed Case MK Nov/09
27 Predictors of Response to Tesamorelin Copyright All Rights Reserved. Property of Theratechnologies Inc.
28 Predictors of Response to Tesamorelin Treatment Mangili A. et al., PLoS One 2015.
29 Predictors of Response to Tesamorelin Treatment (Cont d) Mangili A. et al., PLoS One 2015.
30 Conclusions EGRIFTA has a unique mechanism of action as it works by stimulating the production of endogenous growth hormone EGRIFTA resulted in statistically significant reductions in VAT and WC at week 26, sustained through week 52 Treatment effect related to duration of treatment and seen as early as 13 weeks GH-related AEs and injection site reactions were more frequent with EGRIFTA Patients with baseline MetS, elevated TG levels, or white race were most likely to experience reductions in VAT after 6 months of treatment Please see EGRIFTA (tesamorelin for injection) full Prescribing Information, Patient Information and Patient Instructions for Use for full disclosure. Copyright All Rights Reserved. Property of Theratechnologies Inc.
31 Effect of Tesamorelin on Liver Fat Copyright All Rights Reserved. Property of Theratechnologies Inc.
32 Rationale and Hypothesis Humans: Patients with pituitary growth hormone deficiency (GHD) have a higher prevalence of NAFLD and NASH than the general population Replacement of GH reduces transaminases and improves histological findings Hypothesis: Tesamorelin will reduce liver fat in association with reductions in VAT. Adams LA et al. Hepatology. 2004; 39: Ichikawa T et al. Gut. 2003; 52:914.
33 H e p a tic L ip id -to -W a te r % Tesamorelin decreases liver fat C h a n g e in L iv e r F a t p = % 0-40% -5 T e s a m o re lin P la c e b o Bars show median, error bars IQR. Tesamorelin: -2.0 [-6.4, 0.1]; Placebo: 0.9 [-0.6, 3.7] Stanley T. et al. JAMA 2014.
34 Correlations between Changes in VAT, Hepatic Fat, and Metabolic Variables A Visceral Adipose Tissue (cm 2 ) C AST (U/L) P Hepatic Lipid-to-Water Percent T T P B = 0.31, P = = 0.50, P = Log10 Triglyceride HOMA-IR Tesamorelin Placebo Hepatic Lipid-to-Water Percent 0.8 r = 0.33, P = 0.03 D r = 0.52, P = T T P P Visceral Adipose Tissue Area (cm 2 ) Stanley T. et al. JAMA Visceral Adipose Tissue Area (cm 2 )
35 Safety of Growth Hormone Recent Publications Copyright All Rights Reserved. Property of Theratechnologies Inc.
36 Diabetic Retinopathy Relationship between serum IGF-1 levels and development of diabetic retinopathy still controversial A large cross-sectional study (N=225) found no association between serum IGF-1 and diabetic retinopathy 1 Increased serum levels of IGF-1 not associated with an increased risk of diabetic retinopathy in a longitudinal study (N-480, 6.2 years of follow-up) 2 1 Payne JF et al., Molecular Vision 2011; 2 Chen HS et al., Eur J Clin Invest 2012.
37 Safety of Growth Hormone (GH) (1) Since 2012, new data have emerged on the potential risk of cancer in patients receiving GH Mortality data from parallel investigations in Belgium, The Netherlands and Sweden show that none of the patients died from cancer or from a CVD 1 No increase increased risk of mortality or incidence of cancer, stroke, or myocardial infarction in adult GHdeficient patients who had previously received pediatric GH treatment (The Hypopituitary Control and Complications Study, a prospective observational study (N= 10,190, US, Canada, and 14 Europeans countries) 2 1 Savendahl L. et al. JCEM 2012; 2 Mo D. et al. Pituitary 2014.
38 Safety of Growth Hormone (GH) (2) Pediatric Endocrine Society Drug and Therapeutics Committee: GH therapy can be safely administered without concerns about an increased risk for neoplasia 1 A statement from the European Society of Paediatric Endocrinology (ESPE), the Growth Hormone Research Society (GRS), and the Pediatric Endocrine Society (PES) concluded that the evidence from the follow-up of thousands of children and adults over tens of thousands of patient years 2 1 Raman J. et al. J Clin Endocrinol Metab. 2015;100: ; 2 Allen D.B. et al..eur J Endocrinol 2016.
39 Safety of Growth Hormone (GH) (3) ENDO 2016: Debate on the safety of GH: Dr. Jean-Claude Carel (Paris, France) vs. Dr. Ron Rosenfeld (Los altos, CA, USA) 1 : Dr. Carel (PI of the French SAGhE study): Risks of long-term GH are plausible, but there is a long way to go before we fully evaluate the longterm safety of GH treatment. The risk of cancer and CVD is debatable. It s difficult to demonstrate causality. Dr. Rosenfeld: GH is safe. I think methodological limitations of the SAGhE study should be recognized. Interpretation of data may not be correct. Mortality is not increased when adjusted for birth weight. The rhgh population differed from the general population in birth weight and birth length. Limitations of the French SAGhE study include: small number of observations, heterogeneous population, failure to reproduce findings outside of France, lack of appropriate control group. 1 ENDO 2016 Endocrine Debates: Are there long-term risks in pediatric growth hormone treatment? Boston, April 2, 2016.
FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EGRIFTA safely and effectively. See full prescribing information for EGRIFTA. EGRIFTA (tesamorelin
More informationDidactic Series. Lipohypertrophy in HIV
Didactic Series Lipohypertrophy in HIV Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic August 14th, 2014 ACCREDITATION STATEMENT: University of California, San Diego School
More informationClinical Policy: Tesamorelin (Egrifta) Reference Number: MA.PHAR.109 Effective Date: 11/16
Clinical Policy: (Egrifta) Reference Number: MA.PHAR.109 Effective Date: 11/16 Last Review Date: 07/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationCLINICAL SCIENCE. 1 4 In such patients, excess central fat is usually visceral, 9,10 Although studies linking increased WC to mortality
CLINICAL SCIENCE Effects of Tesamorelin, a Growth Hormone Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension Julian
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationNAFLD AND TYPE 2 DIABETES
NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationPitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age
Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Craig A. Sponseller, Masaya Tanahashi, Hideki Suganami,
More informationLEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME
LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME Diana A. Chirinos, Ronald Goldberg, Elias Querales-Mago, Miriam Gutt, Judith R. McCalla, Marc Gellman and Neil Schneiderman
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationMetabolic Syndrome in Asians
Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly
More informationUMHS-PUHSC JOINT INSTITUTE
Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,
More informationSupplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups
Supplemental Table S1: Unadjusted and Adjusted Hazard Ratios for Diabetes Associated with Baseline Factors Considered in Model 3 SMART Participants Only Unadjusted Adjusted* Baseline p-value p-value Covariate
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery
More informationGrowth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials
DOI: 10.1111/j.1468-1293.2010.00906.x r 2011 British HIV Association HIV Medicine (2011), 12, 453 462 REVIEW Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled
More informationObesity, Metabolic Syndrome, and Diabetes: Making the Connections
Obesity, Metabolic Syndrome, and Diabetes: Making the Connections Alka M. Kanaya, M.D. Associate Professor of Medicine & Epi/Biostats University of California, San Francisco February 26, 21 Roadmap 1.
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationIs Tesamorelin a Safe and Effective Drug to Treat Lipodystrophy in HIV Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Tesamorelin a Safe and Effective Drug
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationRoadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total
Diabetes and the Metabolic Syndrome in the Asian Population Alka Kanaya, MD Associate Professor of Medicine, UCSF Feb 26, 2010 Roadmap 1. Diabetes in Asian Americans Prevalence in the U.S. Risk factors
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationAdiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance.
ORIGINAL ARTICLE Adiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance. Bonneau GA y Pedrozo WR 1 Ministry of Public Health, Province of Misiones, 2 School of Exact, Chemical
More informationElevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with
Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with Insulin Resistance Mehrnoosh Shanaki, Ph.D. Assistant Professor of Clinical Biochemistry Shahid Beheshti
More informationRehabilitation and Research Training Center on Secondary Conditions in Individuals with SCI. James S. Krause, PhD
Disclosure The contents of this presentation were developed with support from educational grants from the Department of Education, NIDRR grant numbers H133B090005, H133B970011 and H133G010160. However,
More informationPATIENTS WITH HUMAN IMMUNOdeficiency
ORIGINAL CONTRIBUTION Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation A Randomized Controlled Trial Janet Lo, MD, MMSc Sung Min You, BA Bridget Canavan, MD James
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More information3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.
U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,
More informationCardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010
Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010 CAVEAT LECTOR 2 CVD-related Mortality in Aging SCI GU
More informationThe Metabolic Syndrome Prof. Jean-Pierre Després
The Metabolic Syndrome 1 Jean-Pierre Després, Ph.D., FAHA, FIAS Quebec Heart and Lung Institute Department of Medicine Université Laval Québec, Canada Reaven s syndrome X Triglycerides HDL cholesterol
More informationMETABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2012 vol. 116, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS Ana-Maria Pelin 1, Silvia Mǎtǎsaru 2 University
More informationVisceral adipose tissue and carotid intimamedia thickness in HIV-infected patients undergoing cart: a prospective cohort study
Beires et al. BMC Infectious Diseases (2018) 18:32 DOI 10.1186/s12879-017-2884-9 RESEARCH ARTICLE Visceral adipose tissue and carotid intimamedia thickness in HIV-infected patients undergoing cart: a prospective
More informationEffects of growth hormone secretagogue receptor agonist and antagonist in nonobese type 2 diabetic MKR mice
Effects of growth hormone secretagogue receptor agonist and antagonist in nonobese type 2 diabetic MKR mice Rasha Mosa (MBCHC, M.D, PhD candidate) School of Biomedical Sciences University of Queensland
More informationHigh and Low GH: an update of diagnosis and management of GH disorders
High and Low GH: an update of diagnosis and management of GH disorders Georgia Chapter-AACE 2017 Laurence Katznelson, MD Professor of Medicine and Neurosurgery Associate Dean of Graduate Medical Education
More informationPrevalence of Comorbidities among HIV-positive patients in Taiwan
Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity
More informationCardiometabolic Side Effects of Risperidone in Children with Autism
Cardiometabolic Side Effects of Risperidone in Children with Autism Susan J. Boorin, MSN, PMHNP-BC PhD Candidate Yale School of Nursing 1 This speaker has no conflicts of interest to disclose. 2 Boorin
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More information3/25/2010. Age-adjusted incidence rates for coronary heart disease according to body mass index and waist circumference tertiles
Outline Relationships among Regional Adiposity, Physical Activity, and CVD Risk Factors: Preliminary Results from Two Epidemiologic Studies Molly Conroy, MD, MPH Obesity Journal Club February 18, 2010
More informationEffect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation A Randomized Clinical Trial
Research Original Investigation Effect of on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation A Randomized Clinical Trial Takara L. Stanley, MD; Meghan N. Feldpausch,
More informationMetabolic defects underlying dyslipidemia in abdominal obesity
Metabolic defects underlying dyslipidemia in abdominal obesity Professor Marja-Riitta Taskinen Department of Medicine, Division of Cardiology Helsinki University Hospital, Finland Disclosures: Honorariums/
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationObesity in the pathogenesis of chronic disease
Portoroz October 16th 2013 Obesity in the pathogenesis of chronic disease Rocco Barazzoni University of Trieste Department of Medical, Surgical and Health Sciences Obesity Trends* Among U.S. Adults BRFSS,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationInsulin Sensitivity and Secretion in Youth: From Normal to Diabetes
Insulin Sensitivity and Secretion in Youth: From Normal to Diabetes Silva A. Arslanian MD Richard L. Day Professor of Pediatrics 1 year Jubilee, The Queen Silvia Children s Hospital Gothenburg, Sweden
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationTiming and tempo of first year growth in relation to cardiovascular and metabolic risk profile in early adulthood
Note: for non-commercial purposes only Timing and tempo of first year growth in relation to cardiovascular and metabolic risk profile in early adulthood Anita Hokken-Koelega Professor of Pediatric Endocrinology
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase
More informationEnergy Balance Equation
Energy Balance Equation Intake Expenditure Hunger Satiety Nutrient Absorption Metabolic Rate Thermogenesis Activity Eat to Live! Live to Eat! EAT TO LIVE Intake = Expenditure Weight Stable LIVE TO EAT
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationFigure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
More informationCt=28.4 WAT 92.6% Hepatic CE (mg/g) P=3.6x10-08 Plasma Cholesterol (mg/dl)
a Control AAV mtm6sf-shrna8 Ct=4.3 Ct=8.4 Ct=8.8 Ct=8.9 Ct=.8 Ct=.5 Relative TM6SF mrna Level P=.5 X -5 b.5 Liver WAT Small intestine Relative TM6SF mrna Level..5 9.6% Control AAV mtm6sf-shrna mtm6sf-shrna6
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationABSTRACT THE ENDOCRINE SOCIETY 2001 ACCEPTED SPONSOR J.D.Wilson, M.D.
STREET C, SCALLY MC. Pharmaceutical Intervention of Anabolic Steroid Induced Hypogonadism - Our Success at Restoration of the HPG Axis. Medicine and Science in Sports and Exercise 2000;32(5)Suppl. High-dose
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationCardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az
Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of
More informationEstablishment of Efficacy of Intervention in those with Metabolic Syndrome. Dr Wendy Russell - ILSI Europe Expert Group
Establishment of Efficacy of Intervention in those with Metabolic Syndrome Dr Wendy Russell - ILSI Europe Expert Group Conflict of interest regarding this presentation: I have no conflict of interest to
More informationFructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희
Fructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희 Introduction Unique characteristics of Fructose Metabolism Mechanism for Fructose-Induced Insulin Resistance Epidemiological Studies
More informationLa sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV
WORKSHOP HCV: la guarigione e il parallelismo tra risposta virologica sostenuta e outcome clinico Milano, 25 Ottobre 2018 Ospedale San Raffaele IRCCS - Sede Turro La sindrome metabolica e il suo impatto
More informationLipids Carbohydrate Protein. Fatty Acids Glycerol. Mono/di-saccarides. Aminoacids. Fat Liver Muscle. Triglycerides Glycogen Protein
Lipids Carbohydrate Protein Fatty Acids Glycerol Mono/di-saccarides Fat Liver Muscle Aminoacids Triglycerides Glycogen Protein Microvascular Macrovascular Diabetes-specific Diabetes-enhanced HbA1c 5.7(6.0)
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationStudy of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults
Study of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults Z.-P. Li 1, M. Zhang 2, J. Gao 3, G.-Y. Zhou 3, S.-Q. Li 1 and Z.-M. An 3 1 Golden
More informationDiagnostic Test of Fat Location Indices and BMI for Detecting Markers of Metabolic Syndrome in Children
Diagnostic Test of Fat Location Indices and BMI for Detecting Markers of Metabolic Syndrome in Children Adegboye ARA; Andersen LB; Froberg K; Heitmann BL Postdoctoral researcher, Copenhagen, Denmark Research
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationPREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS
PREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS Mehmet Emre Atabek,MD,PhD Necmettin Erbakan University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology and
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationStudy No.: 49653/020 Title: A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of
Study No.: 49653/020 Title: A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered
More informationIncreasing Growth Hormone with and without using Growth Hormone
Increasing Growth Hormone with and without using Growth Hormone Edwin Lee, M.D., F.A.C.E. Institute for Hormonal Balance Orlando, FL Disclosure The following potential conflict of interest relationships
More information2011, Editrice Kurtis
J. Endocrinol. Invest. : -, 2011 DOI: 10.2/902 The role of visfatin in the pathogenesis of gestational diabetes mellitus D.E. Gok 1, M. Yazici 1, G. Uckaya 1, S.E. Bolu 1, Y. Basaran 2, T. Ozgurtas, S.
More informationOther Ways to Achieve Metabolic Control
Other Ways to Achieve Metabolic Control Nestor de la Cruz- Muñoz, MD, FACS Associate Professor of Clinical Surgery Chief, Division of Laparoendoscopic and Bariatric Surgery DeWitt Daughtry Family Department
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationSupplementary Online Content
Supplementary Online Content Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autistic spectrum disorder:
More informationRelationship of Waist Circumference and Lipid Profile in Children
International Journal of Biomedical Science and Engineering 2015; 3(3): 44-48 Published online May 28, 2015 (http://www.sciencepublishinggroup.com/j/ijbse) doi: 10.11648/j.ijbse.20150303.12 ISSN: 2376-7227
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationNOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet
NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet FASTING 16 hours a day EXCERCISE 150 min a week DIET Low carb NOSM Northern Research Conference, Kenora, 2018 R Minty, T O Driscoll, L Kelly,
More informationAUTONOMIC FUNCTION IS A HIGH PRIORITY
AUTONOMIC FUNCTION IS A HIGH PRIORITY 1 Bladder-Bowel-AD Tetraplegia Sexual function Walking Bladder-Bowel-AD Paraplegia Sexual function Walking 0 10 20 30 40 50 Percentage of respondents an ailment not
More informationEndocrinopathy and Leukocyte Telomere Length in HIV+ Individuals in the CARMA Cohort
Endocrinopathy and Leukocyte Telomere Length in HIV+ Individuals in the CARMA Cohort Kristen M. Sokalski, Alice Mai, Jackson Chu, Hélène Côté, Evelyn J. Maan, Arianne Albert, Neora Pick, Deborah Money,
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More informationHypothalamic & Pituitary Hormones
1 Hypothalamic & Pituitary Hormones Pharmacologic Applications: Drugs that mimic or block the effects of hypothalamic or pituitary hormones have the following applications: 1. Replacement therapy for hormone
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None BURDEN OF CORONARY ARTERY DISEASE IN DIABETES IN INDIA Amal Kumar Banerjee MD, DM,FACC,FESC,FACP,FAPSC,FICC President Association of Physicians of India SAARC Cardiac
More informationObesita e sindrome metabolica
Obesita e sindrome metabolica S. Bernasconi Dipartimento età evolutiva Clinica Pediatrica Università di Parma sbernasconi@ao.pr.it Obesita e sindrome metabolica 2500 PUBMED : 2000 Obesity 1500 Ultimo anno
More informationMetabolomics in nutrition research: biomarkers predicting mortality in children with severe acute malnutrition
Metabolomics in nutrition research: biomarkers predicting mortality in children with severe acute malnutrition Michael Freemark Department of Pediatrics, Duke University Medical Center, the Duke Molecular
More informationD:A:D Study Teaching Material
D:A:D Study Teaching Material Data Collection of Adverse events of anti-hiv Drugs (D:A:D) study December 2012 - CHIP Background The D:A:D Study, is a prospective cohort study (collaboration) initiated
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationThe role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
More information2/10/2016. Patient-Centered Management of Dyslipidemia. No disclosures. What is Patient-Centered Management?
Patient-Centered Management of Dyslipidemia Carl E. Orringer, MD, FACC, FNLA Associate Professor of Medicine University of Miami Miller School of Medicine President, National Lipid Association 1 No disclosures
More informationDepartment of Endocrinology, First Affiliated Hospital of Chongqing Medical University, Chongqing , China
842 2016 10 1 41 10 [ ] (AGHD) (VAI) C (hs-crp) 6(IL -6) 40 AGHD 40 (BMI) (WHR) VAI (WHtR) (LAP) (HOMA-IR) (HOMA- ) (LDL-C)/ (HDL-C) (TC)/HDL-C (TG)/LDL -C AGHD BMI (WC) WHR (FINS) HOMA- HOMA- IR TC TG
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationOptimizing Postpartum Maternal Health to Prevent Chronic Diseases
Optimizing Postpartum Maternal Health to Prevent Chronic Diseases Amy Loden, MD, FACP, NCMP Disclosures Research: None Financial: none applicable to this presentation PRIUM QEssentials Market Research
More information